Intravenous-oral itraconazole versus oral posaconazole in preventing invasive fungal diseases for acute leukemia patients  

作　　者：Li Liua Xiaolei Peia Runzhi Maa Yi Hea Rongli Zhanga Jialin Weia Qiaoling Maa Weihua Zhaia Aiming Pang Erlie Jiang Mingzhe Han Donglin Yang Sizhou Feng 

机构地区：[1]Hematopoietic Stem Cell Transplantation Center,National Clinical Research Center for Blood Diseases,State Key Laboratory of Experimental Hematology,Haihe Laboratory of Cell Ecosystem,Institute of Hematology&Blood Diseases Hospital,Chinese Academy of Medical Sciences&Peking Union Medical College,Tianjin 300020,China

出　　处：《Blood Science》2023年第2期106-110,共5页血液科学（英文）

基　　金：the Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences(CIFMS)[2021-I2M-1-017]and[2021-I2M-C&T-B-080];Haihe Laboratory of Cell Ecosystem Innovation Fund[HH22KYZX0036].

摘　　要：Invasive fungal diseases(IFDs)are major and lethal infectious complications for patients with neutropenia after chemotherapy.Prophylaxis with intravenous and oral suspended itraconazole(200 mg Q12h intravenously×2 days followed by 5 mg/kg·d orally in twice)or oral suspension of posaconazole(200 mg Q8h)was administered for preventing IFDs.The only 2 episodes of proven IFDs were not included after propensity-score matching(PSM),while the incidence of possible IFDs was 8.2%(9/110)in itraconazole group and 1.8%(2/110)in posaconazole group,respectively(P=.030).In clinical failure analysis,the failure rate of posaconazole group was lower as compared to the itraconazole group(2.7%vs 10.9%,P=.016).Both intravenous-oral itraconazole and posaconazole suspension are effective in preventing IFDs,while posaconazole suspension seems more tolerable.

关 键 词：Acute leukemia Antifungal prophylaxis Invasive fungal disease ITRACONAZOLE POSACONAZOLE 

分 类 号：R733.71[医药卫生—肿瘤]